A large delegation of researchers representing several research labs at iBET participated in the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) in Brussels, Belgium, held from October 24-27th.
The event served as an international platform for key figures in the field to collaborate, showcase and discuss the latest advancements in Gene Therapy, Cell Therapy and Genetic Vaccines.
The iBET team showcased their expertise with one oral presentation and several poster presentations:
- Pedro Vicente – Advancing the manufacture of hiPSC-derived cardiomyocytes in bioreactors through WnT activation and dissolved oxygen control (oral presentation)
- Mariana Valentim Ferreira – Improving AAV packaging capacity by enhanced protein trans-splicing at low dual vector doses (poster)
- Sofia Fernandes – Insights into AAV promoter activity and helper virus components interactions (poster)
- Rodrigo Nogueira – Using a cell receptor knock-out strategy to enable stable expression of cytotoxic envelope glycoproteins for lentiviral vector production (poster)
- Eunice Gonçalves – Cell-based proteolytic sensing systems: platforms for vaccine and antiviral development (poster)
- Catarina Gomes – Human stem-cell based models to study innate immunity and neuroinflammation in the central nervous system (poster)
- Isabella Ramella Gal – Towards human innate immune-competent 3D hepatic models to address early tissue response to therapeutic AAV vectors (poster)
- Margarida Costa – Expansion and T cell phenotype can be tuned in stirred tank bioreactors through temporal control of T cell activation stimuli (poster)
- Hélio Tomás – Increasing the efficiency of lentiviral transduction to manufacture chimeric antigen receptor targeting HER2 in stirred-tank bioreactors (poster)
Moreover, other scientists from iBET, including Francisca Arez, Gabriela Silva, Catarina Brito, Sofia Coroadinha, and Carina Silva, also attended the conference.
Established in 1992, ESGCT seeks to promote basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.